Research view — this content is science-dense and intended for informed readers. It reflects published preclinical and clinical literature. Nothing here constitutes medical advice.

01 — Evidence

Evidence Summary

Baicalin's oncology evidence is preclinical-dominant. There is no controlled human trial of tumor regression, biomarker response, or survival — purified baicalin has reached people only in small pharmacology studies, and most human data describe it as the circulating metabolite of oral baicalein. Underneath sits broad, repeatedly positive animal tumor-model work and a large in-vitro mechanistic literature, read against the gap between laboratory-active concentrations and the low plasma levels a poorly absorbed glucuronide reaches orally.

Human

Clinical Record

No oncology trials

Baicalin has no clinical oncology evidence. Purified baicalin has been given to healthy volunteers only in small pharmacology studies, and its main human pharmacokinetic record comes from trials of oral baicalein, where baicalin is a major circulating metabolite.

  • No controlled trial has tested tumor regression, biomarker response, or survival
  • Registered studies use baicalin only within multi-ingredient interventions (Parkinson's support, a cognition supplement, a topical dressing, a herbal-injection registry) — none in oncology
  • Purified oral baicalin has been used only in small tolerability and drug-interaction studies
No oncology trials yet

Animal

Preclinical Signal

Broad xenograft outcomes

Baicalin suppressed tumor growth across many cancer types — mostly by intragastric dosing, some by injection — often enhancing chemotherapy or radiotherapy rather than acting on its own.

  • Shrank colorectal, hepatocellular, prostate, chondrosarcoma, glioblastoma and other xenografts
  • Reversed EMT and lowered metastasis in an orthotopic colorectal model
  • Induced tumor ferroptosis and drove cellular senescence in living tumors
Broad across tumor types

In Vitro

Cell Model Data

Mechanistic; concentration-limited

Across diverse cancer lines baicalin suppresses proliferation, migration and survival signaling and triggers tumor-cell death by several routes — but the effective concentrations sit above the plasma levels a poorly absorbed glucuronide reaches orally.

  • Suppressed STAT3, PI3K–AKT–mTOR, ERK and Wnt/β-catenin survival signaling
  • Induced mitochondrial apoptosis, tumor ferroptosis and cellular senescence
  • Lower toxicity to matched normal-cell models at active doses (not tumor selectivity in vivo)
Concentration gap caveat

Human

Clinical Record

Baicalin has no clinical oncology evidence: no controlled trial has tested tumor regression, biomarker response, or survival. Purified oral baicalin has reached people only in small pharmacology studies — a single 500 mg dose was well tolerated, and a 50 mg three-times-daily regimen was used to probe a transporter interaction[55,58]; an older report also gave ten subjects a single 1 g oral dose to characterize urinary metabolites.[66]

Continue reading — full research detail+

ClinicalTrials.gov contains only non-oncology studies in which baicalin appears as one component of a multi-ingredient intervention — a Parkinson's-disease nutritional-support arm, a cognition supplement standardized to a Scutellaria–Acacia extract, a multi-ingredient topical wound dressing, and a safety registry for a Scutellaria-containing injection — never as a standalone anti-cancer agent. No trial has measured baicalin's own peak concentration or oral bioavailability; the human pharmacokinetic picture is read instead from trials of oral baicalein, in which baicalin is a major circulating metabolite.[53,64]

Signal maturity: preclinical-dominant. The human evidence establishes tolerability and measurable exposure, not anti-tumor activity; every oncology-relevant claim on this page rests on animal or cell-model data, read against the pharmacokinetic gap below.

Animal

Preclinical Signal

Tumor-model outcomes are broad and repeatedly positive across colorectal, breast, hepatocellular, gastric, prostate, osteosarcoma, chondrosarcoma, lung, glioblastoma and nasopharyngeal systems — delivered mostly by intragastric dosing, with some xenografts treated by intraperitoneal injection.[2,13,62]

Continue reading — full research detail+

Intragastric baicalin dose-dependently degraded hexokinase-2 and shrank colorectal tumors while repolarizing tumor-associated macrophages[13]; in an orthotopic colorectal model it suppressed growth and metastasis to lymph node, liver and pancreas while reversing EMT and lowering cancer-stem-cell markers[2]; and it suppressed hepatocellular[23], chondrosarcoma[19], prostate cancer-stem-cell[10], lung[28] and glioblastoma[62] xenografts. It induced ferroptosis and shrank osteosarcoma tumors through an Nrf2/xCT/GPX4 axis[32], and reduced tumor onset in a urethane-induced lung model by restoring SOCS1.[9]

A recurring pattern is enhanced tumor suppression when baicalin is combined with chemotherapy or radiotherapy — 5-FU in a breast/Ehrlich model[6], oxaliplatin in resistant gastric cells[34], radiotherapy in radioresistant nasopharyngeal cells[15], and cisplatin in resistant lung cells[36] — rather than a standalone effect. One study found the anti-tumor effect not dose-proportional, a lower intragastric dose outperforming a higher one.[2]

Signal maturity: the animal work is the strongest translational tier currently available, reported across many tumor types — though by different routes, doses, and schedules that cannot be converted into a human tumor exposure. What it establishes is that whole-organism metabolism and baicalin's interconversion cycle do not abolish its activity.

In Vitro

Cell Model Data

Across diverse cancer lines baicalin suppresses proliferation, migration and invasion, arrests the cell cycle, and reduces survival signaling through STAT3, PI3K–AKT–mTOR, ERK and NF-κB; it induces mitochondrial apoptosis, tumor-directed ferroptosis, and — distinctively — cellular senescence, and reverses EMT markers. The load-bearing caveat is concentration.

Continue reading — full research detail+

Several studies report lower toxicity to selected normal-cell models — no effect on normal chondrocytes at doses cytotoxic to chondrosarcoma[19], no toxicity to normal human astrocytes up to 300 µM while killing glioblastoma cells[62], and a migration/invasion block in breast cells at concentrations that did not change viability.[1]

As with most flavonoids, the effective in-vitro concentrations — often tens to low-hundreds of micromolar (Burkitt-lymphoma apoptosis IC50 ~10 µM[20]; prostate cancer-stem-cell effects ~125 µM[10]; hepatocellular ferroptosis ~200 µM[35]) — generally exceed the plasma levels reachable orally, given baicalin's poor intact absorption.

Signal maturity: the in-vitro mechanistic case is deep and consistent — apoptosis, ferroptosis and senescence all reproduced — but most targets require concentrations above the plasma level an oral glucuronide reaches, which is why the animal work carries the translational read. Dominant evidence tier: preclinical.

Advertisement

Ad space

02 — Pathways

Pathway Interaction Profile

In laboratory and animal research, baicalin has been reported to engage several distinct biological pathways relevant to tumor behavior, grouped below by the functional role each one supports. These include direct anti-tumor mechanisms and, further down, a separate set of pathways reported to support the body's own resilience. All five roles are read as partial: the mechanisms are reproduced in laboratory and animal systems, but human oral pharmacokinetics sit below the concentrations active in the laboratory, and no human oncology outcome has been measured.

Contain Partial evidence

Baicalin's Contain classification rests on anti-metastatic activity reproduced across several animal models, anchored by a consistent EMT-reversal node — β-catenin-dependent EMT reversal in aggressive breast cells and TGF-β1/Smad-linked EMT suppression that reduced growth and metastasis in an orthotopic colorectal model. Its anti-angiogenic and anti-stemness arms are genuine but double-edged, with opposite-direction findings, so they are carried with the direction stated. It is read as partial because the effective exposures were reached in animal and in-vitro systems, and human oral pharmacokinetics sit below the in-vitro effective range.

Prevent Tumor Cell Shedding

Research concerning pathways related to invasion and escape from existing lesions, including EMT and ECM-breach mechanisms.

ID 61

EMT & metastatic invasion

Baicalin's strongest Contain node. In highly aggressive breast cancer cells it reversed epithelial–mesenchymal transition by suppressing β-catenin signaling, restoring E-cadherin and lowering mesenchymal markers, and cutting migration and invasion at concentrations that did not change cell viability — marking the effect as anti-metastatic rather than merely cytotoxic.[1] In an orthotopic colorectal model it reversed EMT (lowering TGF-β1/Smad2/3/4 and N-cadherin/vimentin/Snail/Slug/Twist, raising Smad7/E-cadherin) and reduced metastasis to mesenteric lymph node, liver and pancreas[2]; in osteosarcoma it blocked TGF-β1-induced EMT and anoikis resistance[3]; and it directly antagonized the β2-adrenergic receptor to curb epinephrine-driven, chronic-stress-facilitated breast-cancer metastasis.[4] In a study of Scutellaria flavonoids the baicalin arm blocked migration and invasion in an Id1-dependent manner.[5]

Block Seeding & Niche Formation

Research concerning pathways related to the formation of supportive pre-metastatic niches at distant sites.

ID 62

Angiogenesis / VEGF / HIF-1α

Carried as double-edged, with the direction stated. In a breast/Ehrlich solid-tumor model baicalin alone reduced tumor growth and angiogenesis and enhanced the effect of 5-fluorouracil[6], and in mesothelioma it lowered VEGF alongside EGFR/AKT/MAPK/S6 signaling.[7] In lung carcinoma, baicalin inhibited HIF-1α and — acting as a superoxide-dismutase mimic — suppressed tumor growth and lung metastasis in vivo without systemic toxicity.[65] However, an independent study reported baicalin increasing VEGF expression and angiogenesis through an ERRα/PGC-1α pathway in a vascular context that included tumor lines[8] — so its VEGF direction is not uniformly suppressive. The anti-angiogenic finding is real and reproduced in an animal tumor, but the opposite-direction data mean this node is not a clean anti-angiogenic mechanism.

ID 56

NF-κB / TNF-α / IL-6 inflammatory axis

Baicalin lowers NF-κB activity as part of several tumor-suppressive programs rather than as a standalone anti-inflammatory tumor mechanism: it restored the negative regulator SOCS1 to shut down an NF-κB/STAT3 axis in lung cancer, reducing tumor burden in a urethane model[9]; lowered NF-κB p65, Survivin and XIAP in the orthotopic colorectal work[2]; and reduced NF-κB p-P65 while antagonizing cancer stemness in prostate cancer-stem-cells in vivo.[10]

Prevent Dormant Reactivation

Research concerning pathways involved in wake-up signalling and reactivation of dormant disseminated tumour cells.

ID 60

Cancer stemness / self-renewal

Carried as double-edged, with the direction stated. Baicalin suppressed cancer-stem-cell traits across several epithelial models — in prostate cancer-stem-cells it lowered CD44/CD133/ALDH1 and Notch1 with in-vivo xenograft suppression, reversed by forced Notch1[10]; in ovarian cancer it reduced sphere-forming and tumor-initiating frequency by suppressing YAP through RASSF6[11]; and in the orthotopic colorectal work it lowered CD133/CD44/SOX2/OCT4/Nanog and inhibited sphere formation.[2] Against this, one study reported baicalin promoting mammary stem-cell self-renewal and accelerating growth of a hormone-receptor-negative breast xenograft[12] — a genuine opposite-direction signal. The anti-stemness direction dominates the epithelial-cancer literature but is not universal.

Starve Partial evidence

Baicalin's Starve classification rests on genuinely tumor-directed metabolic pressure, but it is preclinical. The clearest mechanism is enzyme-level — degradation of hexokinase-2, the first and rate-limiting enzyme of glycolysis — rather than a broad transcriptional program, alongside context-dependent modulation of autophagy.

Glucose Axis Pressure

Research concerning pathways related to glycolytic ATP production and the generation of intermediates used by cancer cells.

ID 24

Aerobic glycolysis (Warburg effect)

Baicalin's strongest Starve node, and mechanistically clean. In colorectal cancer baicalin engaged hexokinase-2 — target engagement supported by drug-affinity-responsive target stability and cellular thermal-shift assays — and promoted its ubiquitin-proteasomal degradation, suppressing aerobic glycolysis and causing mitochondrial damage; the released mitochondrial DNA engaged cGAS/STING to repolarize tumor-associated macrophages toward the M1 phenotype, and intragastric baicalin (20 and 40 mg/kg daily for 21 days) reduced tumor growth in vivo.[13] Glycolytic enzymes other than hexokinase-2 returned no purified-baicalin oncology evidence, so this node rests specifically on the hexokinase-2 mechanism.

Metabolic Flexibility Suppression

Research concerning pathways involved in metabolic adaptation and switching between fuel sources under pressure.

ID 71

Autophagy & lysosomal system

Baicalin modulates autophagy in opposite directions by tumor type, so it is carried as context-dependent. In non-small-cell lung cancer it killed cells by blocking autophagic flux — activating the lysosomal channel MCOLN3, disrupting lysosomal function so autolysosomes could not clear, and driving mitochondrial depolarization and apoptosis, with xenograft suppression[14]; in nasopharyngeal carcinoma it suppressed cytoprotective autophagy to reverse radioresistance and lower the surviving fraction after irradiation[15]; whereas in bladder cancer it induced pro-death autophagy through AKT inhibition[16], and in hepatocellular cells it drove autophagic death linked to CD147 downregulation.[17]

Weaken Partial evidence

Baicalin's broadest, best-corroborated role — survival- and proliferation-signaling suppression consistent across cancer types, several nodes with xenograft confirmation, plus a cellular-senescence signature distinct from its aglycone. Read as partial because human oral pharmacokinetics sit below the concentrations active in the laboratory.

Expansion Suppression

Research concerning pathways related to proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.

ID 46

JAK/STAT (STAT3)

A well-corroborated node with an unusual mechanism. In lung cancer baicalin restored the negative regulator SOCS1 to shut down an NF-κB/STAT3 axis, lowering A549 proliferation and reducing tumor number in a urethane-induced mouse model (intragastric 50/100/200 mg/kg)[9]; in cervical cancer it lowered phospho-STAT3 through inhibition of protein kinase C, reducing proliferation and invasion and raising apoptosis.[18]

ID 41

PI3K–AKT–mTOR (signaling)

In chondrosarcoma baicalin lowered p-PI3K/AKT/mTOR to trigger mitochondrial apoptosis and inhibited xenograft growth without weight loss, sparing normal chondrocytes[19]; in Burkitt lymphoma it down-regulated PI3K/Akt to induce apoptosis (IC50 ~10 µM)[20]; in osteosarcoma a ROS rise co-suppressed PI3K/AKT/mTOR alongside ERK1/2 and β-catenin[21]; and in mesothelioma it lowered p-EGFR/AKT/MAPK/S6 with cell-cycle arrest.[7]

ID 40

RAS–RAF–MEK–ERK (MAPK)

ERK suppression appears as part of baicalin's multi-node signaling block — co-suppressed with PI3K/AKT and β-catenin in osteosarcoma[21] and with EGFR/AKT/S6 in mesothelioma.[7] Notably, ERK signaling runs in the opposite direction in baicalin's senescence program, where Ras/Raf/MEK/ERK activation is part of the growth-arrest mechanism[26] — so this node is context-specific, not a blanket ERK block.

ID 43

Wnt / β-catenin

In colon cancer baicalin lowered miR-217 to raise the Wnt antagonist DKK1, reducing β-catenin and c-Myc[22]; in aggressive breast cancer β-catenin suppression drove the EMT reversal above[1]; in hepatocellular carcinoma it suppressed ROCK1 to lower phospho-GSK-3β and β-catenin, forcing G0/G1 arrest and inhibiting xenograft growth and metastasis[23]; and the osteosarcoma ROS mechanism also lowered β-catenin.[21]

ID 51

Cell cycle & cellular senescence

Baicalin produces cell-cycle arrest by lowering cyclins — in hepatic cancer cells it drove S-phase accumulation with reduced Cyclin A, CDK2 and Cyclin D1 and suppressed tumor growth in vivo[24], and the hepatocellular ROCK1 work forced G0/G1 arrest.[23] Distinctively, baicalin also drives cellular senescence where its aglycone drives apoptosis: in colon cancer it induced senescence by inhibiting telomerase reverse transcriptase (TERT), confirmed in humanized-mouse xenografts and set directly against baicalein's apoptotic action in the same system[25]; an independent study confirmed senescence via up-regulation of DEPP with Ras/Raf/MEK/ERK and p16/Rb activation, reversible by DEPP knockdown and reducing xenograft growth.[26]

Metabolic Weakening

Research concerning pathways related to tumour metabolic competence and adaptive capacity over time.

ID 33

Epigenetic regulation & transcriptional control

Baicalin is the first flavone-based natural inhibitor of the histone demethylase LSD1 (KDM1A). In gastric cancer cells over-expressing LSD1 it inhibited the enzyme (IC50 ~3 µM) and engaged it inside cells — raising H3K4me2 without changing LSD1 protein levels, and reversibly (activity recovered on dilution) — while inhibiting proliferation (IC50 ~9 µM) and migration and shifting EMT markers (E-cadherin up, N-cadherin down).[67] These effects sit in the low-micromolar range, nearer the orally achievable exposure than most nodes on this page — though still an in-vitro finding.

Attack Partial evidence

Baicalin's Attack classification rests on direct tumor-cell death by several routes — preclinical, with the systemic-exposure caveat. Unlike its aglycone baicalein, baicalin's ferroptosis direction is tumor-suppressive.

Direct Tumor-Directed Killing

Research concerning pathways related to regulated tumour-cell death pathways, including apoptosis, ferroptosis, and necroptosis.

ID 48

Intrinsic apoptosis (mitochondrial / Bcl-2)

A reproduced Attack mechanism with a consistent Bax↑/Bcl-2↓/caspase-9→-3 signature: prostate cancer (nuclear fragmentation, most sensitive line ~50% growth inhibition)[27]; non-small-cell lung cancer, where the parent compound raised apoptosis via reduced p-Akt and inhibited tumor growth by ~35% in nude mice[28]; cervical cancer, engaging both mitochondrial and death-receptor arms[29]; and Burkitt lymphoma through PI3K/Akt down-regulation.[20] In glioblastoma it drove mitochondrial apoptosis with pro-death autophagy through a Ca²⁺-dependent PI3K/AKT/mTOR mechanism, was non-toxic to normal human astrocytes up to 300 µM, and suppressed a xenograft given intraperitoneally.[62] In leukemia baicalin was weak alone but strongly augmented hyperthermia-induced apoptosis.[30]

ID 49

Extrinsic apoptosis (death receptors)

Baicalin overcomes TRAIL resistance: in non-small-cell lung cancer it sensitized TRAIL-resistant cells through p38 MAPK activation and ROS production, increasing PARP cleavage and Annexin-V positivity[31]; the cervical study above also engaged the Fas/FasL/caspase-8 death-receptor arm.[29]

ID 65

Ferroptosis (execution / cell death)

A genuine positive Attack node for baicalin — and a point of divergence from baicalein, which is a net ferroptosis inhibitor. Baicalin induced tumor ferroptosis across five separate tumor models by suppressing the GPX4/xCT antioxidant axis, each rescued by the ferroptosis inhibitor ferrostatin-1: osteosarcoma (binding Nrf2 to drive its degradation, with xenograft suppression)[32]; lung cancer (by up-regulating the lipoxygenase ALOX12, the opposite of baicalein's lipoxygenase inhibition)[33]; oxaliplatin-resistant gastric cancer (p53-driven, re-sensitizing the cells)[34]; hepatocellular carcinoma (ROS–PI3K/Akt/FoxO3a)[35]; and colorectal cancer, where it up-regulated the mitochondrial iron transporter SLC25A28 to suppress the electron-transport-chain subunit UQCRC2 — an antitumor effect shown in xenografts to depend on both SLC25A28 and ferroptosis.[63] In normal tissue baicalin can instead act as a ferroptosis inhibitor, so the tumor-directed pro-ferroptotic action is context-specific.

ID 54

DNA damage & repair (XRCC1 repair attenuation)

A chemo-sensitizing mechanism rather than standalone killing: in cisplatin-resistant lung cancer baicalin lowered the base-excision-repair scaffold XRCC1, increasing DNA damage and S-phase arrest and restoring cisplatin sensitivity — XRCC1 overexpression blunted the effect and knockdown enhanced it.[36]

Protect Partial evidence

Baicalin's Protect classification rests on host benefits that are real but entirely preclinical — no human host-outcome evidence exists — so the role is partial. Oncology Host-Status carries the chemoprevention and chemotherapy-sensitization evidence; Disease-Resilience carries the organ-protection findings, several of which sit directly in a chemotherapy-toxicity context.

Oncology Host-Status

Chemoprevention & chemo/radiotherapy sensitization — in a breast/Ehrlich solid-tumor model baicalin alone slowed growth and, combined with 5-fluorouracil, enhanced the antitumor effect, reported as a chemopreventive action.[6] In gastric cancer cells, baicalin enhanced 5-fluorouracil by promoting ROS-mediated, Ferrostatin-1-rescuable ferroptosis (in vitro).[68] Two reviews of the flavone pair corroborate a recurring chemoprevention and chemo/radiotherapy-sensitization pattern and note baicalin's favorable tolerability even at relatively high oral doses, limited by solubility and bioavailability.[43,44] These are prevention and combination findings, not evidence for treating established cancer.

Hepatic Resilience & Clearance

Human and preclinical research concerning hepatic enzyme systems, bile-acid handling, xenobiotic metabolism, and liver-related clinical markers.

Cisplatin hepatoprotection & anti-fibrotic liver

A baicalin nanoemulsion (10 and 20 mg/kg) reduced cisplatin-induced rises in serum liver enzymes, oxidative stress, inflammation and hepatic DNA damage in rats, outperforming a conventional suspension[38] — a host-protection finding during platinum chemotherapy. Separately, in a methionine–choline-deficient steatohepatitis model baicalin lowered hepatic lipid, inflammation and NF-κB and the fibrotic markers α-SMA/TGF-β1/Col1A1[39], and in diethylnitrosamine-induced cirrhosis it lowered collagen-I, α-SMA and TGF-β1 and improved liver enzymes and antioxidants.[40] These toxicity-protection models did not test whether host protection came at the cost of the chemotherapy's antitumor effect.

Other Organ-System Reserve

Research concerning renal, cardiac, pulmonary, and other non-hepatic organ-system reserve under systemic or treatment-related stress.

Anthracycline cardioprotection

Baicalin's most cancer-relevant organ-protection signal. In doxorubicin-treated mice, oral baicalin (100 mg/kg for four weeks) prevented rises in cardiac troponin-I, CK-MB, LDH and transaminases, suppressed a TLR4/NF-κB/IL-1β inflammatory axis, restored Wnt/β-catenin signaling and lowered oxidative stress.[37] This is a preclinical host-protection finding during anthracycline exposure — a cardiotoxicity model that did not test whether cardioprotection occurred without reducing doxorubicin's antitumor efficacy.

GI Integrity & Microbiome

Research concerning gut-barrier integrity and inflammatory tone in the host.

Colitis & barrier protection

An oral baicalin amorphous solid dispersion markedly reduced inflammatory infiltration and preserved mucosal architecture in dextran-sulfate-sodium colitis, outperforming unformulated baicalin.[42] Potentially relevant to GI resilience, though not tested in treatment-induced mucositis; preclinical (mouse).

Host-Selective Redox Buffering

Studies evaluating whether redox buffering can be supported in normal host tissues selectively, separately from tumor-cell redox vulnerability.

Direction-selective redox — a proposed dual-benefit pattern

Baicalin shows a redox direction-selectivity between compartments: inside tumor cells it can act pro-oxidant/pro-ferroptotic — raising ROS and iron and suppressing GPX4 to drive ferroptotic death (Attack, e.g. osteosarcoma[32], hepatocellular[35]) — while in normal host tissue the same molecule is protective, scavenging cisplatin-induced lipid peroxidation in human erythrocytes[41] and restoring antioxidant defenses in heart, liver and kidney injury models.[37,38,40]

Because the tumor pro-oxidant and host antioxidant findings come from different tissues, doses and systems — and baicalin can also protect normal cells from oxidative death — a clinically selective tumor-versus-host window is not demonstrated; it is a reason to investigate, not proof.

Prevent Tumor Cell Shedding

Research concerning pathways related to invasion and escape from existing lesions, including EMT and ECM-breach mechanisms.

Contain
ID 61

EMT & metastatic invasion

Baicalin reversed epithelial–mesenchymal transition and cut migration and invasion across breast, colorectal and osteosarcoma models — restoring E-cadherin and suppressing β-catenin and TGF-β1/Smad signaling — and lowered metastasis in an orthotopic colorectal model. Its anti-angiogenic and anti-stemness effects are real but carry opposite-direction findings, so they are held as double-edged.

Glucose Axis Pressure

Research concerning pathways related to glycolytic ATP production and the generation of intermediates used by cancer cells.

Starve
ID 24

Aerobic glycolysis (Warburg effect)

Baicalin engaged and degraded hexokinase-2 — the first, rate-limiting enzyme of glycolysis — collapsing tumor glucose metabolism and, downstream, prompting an immune shift toward tumor-fighting macrophages, with tumor suppression in a colorectal model dosed by mouth. It also blocks or redirects autophagy depending on the tumor type.

Expansion Suppression

Research concerning pathways related to proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.

Weaken
ID 51

Cell cycle & cellular senescence

Alongside suppressing STAT3, PI3K–AKT–mTOR, ERK and Wnt/β-catenin survival signaling, baicalin arrested the cell cycle and — distinctively — pushed tumor cells into cellular senescence, a lasting growth arrest, where its aglycone baicalein instead triggers apoptosis. Several nodes were confirmed in xenografts.

Direct Tumor-Directed Killing

Research concerning pathways related to regulated tumour-cell death pathways, including apoptosis, ferroptosis, and necroptosis.

Attack
ID 48

Intrinsic apoptosis (mitochondrial / Bcl-2)

Baicalin killed tumor cells by more than one route: mitochondrial apoptosis across lymphoma, prostate, lung and glioblastoma models; sensitization to the death signal TRAIL; and — unlike baicalein — reproducible tumor ferroptosis across five cancer types, several confirmed in living tumors. It also lowered a DNA-repair protein to make resistant cells more sensitive to cisplatin.

Host-Selective Redox Buffering

Studies evaluating whether redox buffering can be supported in normal host tissues selectively, separately from tumor-cell redox vulnerability.

Protect
Protect

Direction-selective redox (proposed)

In animal studies baicalin acts pro-oxidant inside tumor cells yet antioxidant in host tissue — guarding heart, liver and kidney under chemotherapy stress and slowing tumors as a chemopreventive — a proposed dual-benefit pattern, but a clinically selective tumor-versus-host switch has not been demonstrated. All host evidence is preclinical.

Advertisement

Ad space

03 — Pharmacokinetics

Pharmacokinetics and Administration

How baicalin moves through the body is the governing limit on this whole profile — and it is unusual. As a large, polar glucuronide with poor aqueous solubility, baicalin is poorly absorbed on its own; much of an oral dose is converted by gut bacteria to baicalein, absorbed, then re-attached to the same sugar and recycled, so blood levels stay low and multi-peaked.

Absorption

Baicalin is a poorly absorbed glucuronide (low solubility and low permeability). Most of an oral dose is hydrolyzed by gut bacteria to baicalein for uptake, so intact-baicalin blood levels are low and rise slowly, with a delayed second peak from recycling.

The Concentration Gap

Laboratory cell-death work sits at tens to hundreds of micromolar, far above the plasma levels an oral glucuronide reaches. Human tumor, intracellular, and unbound exposure remain unknown.

Clinical Dose Context

Purified oral baicalin has reached people only in small pharmacology studies — a single 500 mg dose and a 50 mg three-times-daily interaction study. No trial has reported baicalin's own peak level or bioavailability, and no oncology dose-finding data exist.

Metabolism

Baicalin and baicalein interconvert continuously: gut bacteria strip the sugar to make baicalein, then intestinal and liver enzymes (mainly UGT1A9) re-attach it, and efflux pumps return baicalin to the bowel — an enterohepatic recycling loop.

Co-Dosing

Baicalin's key interactions are transporter-mediated — in people it lowered rosuvastatin exposure via OATP1B1 — and it has preclinical antiplatelet activity. The full table appears in Research view.

Formulation

Formulation can materially raise baicalin exposure in animal studies. A lab phospholipid-complex system raised relative oral bioavailability to ~220% of unformulated baicalin in rats — an experimental comparator, not a property of oral base baicalin or of any retail product.

Absorption

Oral baicalin is poorly absorbed intact. It is a BCS class IV compound — low aqueous solubility and low intestinal permeability — so passive uptake of the intact glucuronide is limited.[48] Only a small fraction is taken up unchanged by intestinal organic-anion-transporting polypeptides (OATP2B1 predominates, with lesser OATP1B1/1B3 uptake).[45] The majority of an oral dose is instead hydrolyzed by gut-microbiota β-glucuronidase — chiefly in the cecum and colon — to the aglycone baicalein, which is lipophilic and readily absorbed; that hydrolysis is the rate-limiting step for absorption.[45] Reported animal exposures are correspondingly low and slow, with unformulated baicalin reaching a plasma peak of only ~0.42 µg/mL at ~5 h in rats.[49]

A characteristic multi-peak plasma profile (a delayed second absorption peak) reflects biliary excretion and enterohepatic recycling, and disappears when recycling is disrupted.[45] Baicalin's clinical activity despite low measured oral bioavailability is best explained by this "microbiota availability" — the molecule behaves in large part as a prodrug for its own aglycone[51], and its circulating metabolites are themselves pharmacologically active.[52]

The Concentration Gap

Many of the cell-death and signaling experiments work at tens to low-hundreds of micromolar — Burkitt-lymphoma apoptosis IC50 ~10 µM[20], prostate cancer-stem-cell effects ~125 µM[10], hepatocellular ferroptosis ~200 µM[35] — well above the plasma levels reachable by an orally dosed, poorly absorbed glucuronide. Human tumor, intracellular and unbound exposure remain unmeasured. The in-vivo animal work shows that first-pass metabolism and the interconversion cycle do not abolish activity — intragastric baicalin suppressed tumors at 20–200 mg/kg across several models[2,13] — but an animal mg/kg dose cannot be equated with a human tumor concentration without species-specific pharmacokinetics.

In-vitro active concentration vs. achievable oral exposure
BenchmarkConcentrationNote
Typical in-vitro mechanistic range~10–200 µMlymphoma IC50 ~10 µM[20]; prostate CSC ~125 µM[10]; HCC ferroptosis ~200 µM[35]
Unformulated baicalin plasma peak (rat, oral)~0.42 µg/mL (~0.9 µM)poorly absorbed intact glucuronide[49]
Human absolute oral bioavailabilityNot publishedno trial has dosed purified oral baicalin and reported its own F%/Cmax[53]
In-vivo animal doses (intragastric)~20–200 mg/kgMC38 20–40 mg/kg[13]; orthotopic CRC 100–200 mg/kg[2] — mg/kg ≠ human exposure

Clinical Dose Context

Human oral baicalin has been given only in a few small pharmacology studies, not oncology trials: chiefly a single 500 mg dose in healthy volunteers[55] and a 50 mg three-times-daily regimen over 14 days used to probe a transporter interaction[58]; an older study gave ten subjects a single 1 g oral dose and characterized its urinary metabolites, but did not report plasma pharmacokinetics.[66] No oncology dose-finding data exist, and no trial has characterized baicalin's own peak concentration or absolute oral bioavailability — the human pharmacokinetic picture is instead read from trials of oral baicalein, in which baicalin is a major circulating metabolite (terminal half-life ~4–11 h, multiphasic profile, combined urinary recovery of the two flavones under 1%).[53] In a multiple-ascending-dose study of oral baicalein (200–800 mg over ten days), baicalin reached steady state around day 8 with a modest accumulation index of ~1.7–2.5.[64] Because circulating drug is largely conjugate and absorption depends on gut-microbiota conversion, laboratory findings should not be assumed to reflect tumor exposure without formulation-specific pharmacokinetic confirmation.

Metabolism

Baicalin sits at the center of a bidirectional interconversion with baicalein. Gut-microbiota β-glucuronidase hydrolyzes baicalin to baicalein for absorption; intestinal and hepatic UDP-glucuronosyltransferases — principally UGT1A9 — then re-conjugate absorbed baicalein back to baicalin.[45,46] In human intestinal (Caco-2) cells, over 90% of apical baicalein was recovered as baicalin, and the glucuronide was effluxed back across the apical membrane by MRP2, not P-glycoprotein.[47] Newly formed baicalin reaching the liver is excreted into bile by BCRP and MRP2 and re-enters the duodenum, driving the enterohepatic recycling and multi-peak plasma profile.[45] This recycling loop, not simple clearance, dominates baicalin's disposition.

Co-Dosing Considerations

Baicalin's most consequential interactions are transporter-mediated, and one is documented in humans. Each row below is flagged by the most cautious guidance the evidence supports.

Discuss whether to combine, separate, or avoid Baicalin and a medication with your treating oncology team or physician.

Co-dosing considerations
FlagInteraction
CautionRosuvastatin (and, by extension, other OATP1B1-transported statins): in healthy volunteers, purified baicalin (50 mg three times daily for 14 days) reduced rosuvastatin exposure — AUC ~42% lower in one OATP1B1 genotype group, genotype-dependent — consistent with reduced OATP1B1-mediated hepatic uptake. This is the one documented human interaction; discuss any statin co-use with the prescriber.[58]
CautionAnticoagulant / antiplatelet drugs. Purified baicalin prolonged aPTT, PT and bleeding time and inhibited thrombin, factor Xa and platelet aggregation in vitro and in mice — an additive-bleeding concern.[57]
CautionEfflux-transporter (BCRP/MRP2) substrate chemotherapeutics — methotrexate, and orally absorbed agents such as sorafenib. A Scutellaria preparation in which baicalin is the main flavonoid raised methotrexate exposure several-fold in rats by inhibiting BCRP and MRP2 efflux[59], and purified baicalin raised oral sorafenib exposure ~2-fold by increasing intestinal absorption[61] — either direction can shift a narrow-index chemotherapeutic's exposure.
MonitorOATP2B1 substrates and co-ingested transporter modulators. Baicalin inhibited OATP2B1-mediated uptake of the irinotecan metabolite SN-38 (a mechanism proposed to reduce irinotecan gut toxicity)[60], and its own exposure is markedly raised by BCRP inhibitors such as rhein[54] — so co-ingested transporter modulators can move baicalin levels in either direction. A single 500 mg dose did not significantly alter cyclosporine pharmacokinetics in humans.[55]

Formulation

Formulation can materially raise baicalin exposure, because the bottleneck is both poor solubility and poor intact permeability. A phospholipid-complex self-microemulsifying system raised the relative oral bioavailability to ~220% of unformulated baicalin in rats[48]; a phospholipid complex alone raised and slowed the plasma peak (0.42→0.90 µg/mL) with a larger overall exposure[49]; a lipid nanocapsule raised oral bioavailability ~2.3-fold[50]; and an arginine amorphous solid dispersion raised plasma exposure and improved a colitis outcome.[42] These are experimental formulation-versus-free comparators in animals — properties of specific research preparations, not of oral base baicalin and not transferable to any commercial "phospholipid" or "liposomal" product without its own pharmacokinetic data.

Advertisement

Ad space

04 — Onset & Washout

Onset and Washout

Baicalin's plasma clock and its studied effect timeline are two different things. Because oral baicalin depends on gut bacteria converting it to baicalein and back, the rise in circulating drug is gradual and multi-peaked rather than sharp, and the preclinical tumor and host effects emerged only over repeated dosing across weeks.

Immediate Onset

Gradual, multi-peak → ~4–11 h half-life

Oral baicalin rises slowly and in multiple peaks because absorption depends on gut-bacterial conversion and enterohepatic recycling; the circulating signal is dominated by the conjugate.

Steady State

~8 days

On repeated dosing, baicalin reached steady state around day 8 with modest accumulation and a delayed second peak from recycling. A consistently bioavailable preparation, not any single dose, governs useful exposure.

Accumulated Effect

Multi-week dosing

The preclinical tumor and host effects emerged over repeated daily dosing across multi-week animal studies — not from single doses.

Dosing Pattern in Studies

Studied as daily use

Human pharmacology studies used once- to three-times-daily oral dosing; preclinical anti-tumor studies used steady daily intragastric dosing over weeks. This is how baicalin was studied, not a recommended regimen.

Washout

How long baicalin stays a relevant factor for co-administered medications before it clears.

Not established

No compound-specific washout interval has been established. Clearance of the free glucuronide is relatively rapid but confounded by enterohepatic recycling, so exposure can persist longer than a simple half-life suggests. Because baicalin has preclinical antiplatelet activity and inhibits the hepatic uptake transporter OATP1B1 (lowering the exposure of drugs that depend on it), interaction timing should be raised with the care team as soon as use begins rather than managed by a fixed window.

What this means in practice: baicalin's blood levels rise gradually and are recycled, and daily dosing reflects what has actually been studied rather than a confirmed requirement. No validated washout period exists — consult your medical team on timing around any antiplatelet, statin/OATP1B1-sensitive, or narrow-therapeutic-index medication, and defer any decision before surgery or a new medication to the treating team.

Two Distinct Clocks

Baicalin's timeline splits into two layers. The direct-pharmacology clock (Immediate Effect) is shaped by its absorption route: because oral baicalin depends on gut-microbiota conversion to baicalein and back, the rise in circulating drug is gradual and multi-peaked rather than sharp, and the systemic signal is dominated by the conjugate.[45,53]

The downstream clock (Accumulated Effect) is where the preclinical tumor and host effects emerged — over repeated daily dosing across multi-week animal studies.[13,37] No measurement here connects the plasma clock to the slow phenotypic clock; sustained, repeated dosing is simply what every study used to reach an effect.

Steady State

No human steady-state parameters for purified oral baicalin have been published. The available human data (baicalin as the major metabolite of oral baicalein) show a multiphasic plasma profile with a terminal half-life of about 4–11 h and a delayed second peak from enterohepatic recycling[53]; on repeated dosing, baicalin reached steady state around day 8 with modest accumulation (index ~1.7–2.5).[64] Because baicalin is poorly absorbed and heavily recycled, consistency of a bioavailable preparation — not any single dose — governs whether useful exposure is reached; carrier formulations raise and sustain exposure.[48,50]

Dosing Pattern in Studies

Human pharmacology studies used once- to three-times-daily oral dosing (single 500 mg; 50 mg three times daily over 14 days)[55,58]; preclinical anti-tumor studies used steady daily intragastric dosing over weeks.[2,13] This describes how baicalin was studied, not a recommended regimen.

Washout

No compound-specific washout interval has been established. Plasma clearance of the free glucuronide is relatively rapid but is confounded by enterohepatic recycling. Because baicalin has preclinical antiplatelet/anticoagulant activity[57] and inhibits the hepatic uptake transporter OATP1B1, lowering the exposure of drugs that depend on it[58], any interaction consideration should be raised with the care team as soon as baicalin use begins rather than managed by a fixed window, and any decision before surgery or a new medication defers to the treating team.

Advertisement

Ad space

05 — Safety

Safety Profile

Purified oral baicalin has been given to healthy volunteers only in small pharmacology studies, and human safety data come mostly from trials of oral baicalein in which baicalin is the major circulating form — generally well tolerated, with mild, self-limiting adverse events and no organ-toxicity signal. Its most consequential safety-adjacent properties are the interaction and off-target ones — detailed under Co-Dosing, not repeated here.

Note on oncology context: the human safety record is limited to short exposure in healthy volunteers, and long-term oncology-specific safety at higher or sustained exposures has not been characterized. The interaction properties — antiplatelet activity and OATP1B1/efflux-transporter effects — carry more weight in cancer patients on other medications and are worth raising with the treating oncology team.

Mild, self-limiting adverse events — a single 500 mg dose of purified baicalin was well tolerated, and human work on oral baicalein (with baicalin as the major metabolite) reported only mild, self-limiting adverse events with no serious events across single doses up to 2800 mg.

Well tolerated on repeated dosing — a ten-day multiple-ascending-dose study of oral baicalein (200–800 mg) was well tolerated, with 44 mild adverse events across 23 of 33 participants and no serious accumulation.

Skullcap-the-herb liver reports are not baicalin — rare liver-injury reports linked to skullcap mostly involve American skullcap in polyherbal products and repeated germander adulteration; the concern attaches to the herb, not to purified baicalin; baicalin's own preclinical hepatoprotection does not by itself establish human hepatic safety.

Adverse Effects in Human Studies

Purified oral baicalin has been given to healthy volunteers only in small pharmacology studies; a single 500 mg dose was well tolerated with no reported safety signal.[55] The human pharmacokinetic work on oral baicalein — in which baicalin is the major circulating metabolite — reported only mild, self-limiting adverse events with no signal of liver or kidney toxicity across single doses up to 2800 mg[53], and a ten-day multiple-ascending-dose study of oral baicalein (200–800 mg) was likewise well tolerated, with 44 mild adverse events across 23 of 33 participants and no serious accumulation.[64] Reviews of the flavone pair describe a favorable tolerability profile even at relatively high oral doses.[44] Long-term oncology-specific safety at higher or sustained exposures has not been characterized.

Liver Safety and the Skullcap Distinction

On liver safety specifically, the picture is reassuring for purified baicalin, and the distinction from the whole herb matters. Baicalin is itself hepatoprotective and anti-fibrotic in preclinical models (carried under Protect, not here). Its preclinical hepatoprotection does not establish human hepatic safety — a compound can protect against one injury model and still cause injury at another exposure — and the long-term hepatic safety of isolated baicalin remains inadequately characterized.

Separately, the NCBI LiverTox liver-injury reports concern Scutellaria/skullcap the herb and cannot be attributed to purified baicalin: LiverTox rates skullcap a likelihood-score "B" cause of rare clinically apparent liver injury, but notes the mechanism is unknown, that implicated products frequently involve American skullcap (S. lateriflora) and repeatedly show germander (Teucrium) adulteration, and that trials of a preparation containing extracted baicalin showed ALT elevations no different from control.[56] The most consequential safety-adjacent properties of purified baicalin are the interaction and off-target ones — antiplatelet/anticoagulant activity and OATP1B1/efflux-transporter effects — detailed under Co-Dosing above.

06 — Sourcing

Sourcing Guide

Formulation can materially change baicalin exposure in preclinical studies, because oral baicalin is limited by both poor solubility and poor intact absorption — much of a dose depends on gut-bacterial conversion; whether any commercial formulation reaches oncology-relevant human exposure is unknown. Our Sourcing Guide lists products we have assessed on formulation, characterization, and brand quality.

Baicalin Sourcing Guide

07 — Literature

References

View references 68 +
  1. Zhou T, Zhang A, Kuang G, Gong X, Jiang R, Lin D, Li J, Li H, Zhang X, Wan J, Li H. Baicalin inhibits the metastasis of highly aggressive breast cancer cells by reversing epithelial-to-mesenchymal transition by targeting β-catenin signaling. Oncol Rep. 2017;38(6):3599-3607. Source ↗
  2. Yang B, Bai H, Sa Y, Zhu P, Liu P. Inhibiting EMT, stemness and cell cycle involved in baicalin-induced growth inhibition and apoptosis in colorectal cancer cells. J Cancer. 2020;11(8):2303-2317. Source ↗
  3. Wang Y, Wang H, Zhou R, Zhong W, Lu S, Ma Z, Chai Y. Baicalin inhibits human osteosarcoma cells invasion, metastasis, and anoikis resistance by suppressing the transforming growth factor-β1-induced epithelial-to-mesenchymal transition. Anticancer Drugs. 2017;28(6):581-587. Source ↗
  4. Jia Q, Zhou Y, Song L, Shi X, Jiang X, Tao R, Wang A, Wu Y, Wei Z, Zhang Y, Li X, Lu Y. Baicalin reduces chronic stress-induced breast cancer metastasis via directly targeting β2-adrenergic receptor. J Pharm Anal. 2024;14(7):100934. Source ↗
  5. Zhao Z, Liu B, Sun J, Lu L, Liu L, Qiu J, Li Q, Yan C, Jiang S, Mohammadtursun N, Ma W, Li M, Dong J, Gong W. Scutellaria Flavonoids Effectively Inhibit the Malignant Phenotypes of Non-small Cell Lung Cancer in an Id1-dependent Manner. Int J Biol Sci. 2019;15(7):1500-1513. Source ↗
  6. Shehatta NH, Okda TM, Omran GA, Abd-Alhaseeb MM. Baicalin; a promising chemopreventive agent, enhances the antitumor effect of 5-FU against breast cancer and inhibits tumor growth and angiogenesis in Ehrlich solid tumor. Biomed Pharmacother. 2021;146:112599. Source ↗
  7. Xu WF, Liu F, Ma YC, Qian ZR, Shi L, Mu H, Ding F, Fu XQ, Li XH. Baicalin Regulates Proliferation, Apoptosis, Migration, and Invasion in Mesothelioma. Med Sci Monit. 2019;25:8172-8180. Source ↗
  8. Zhang K, Lu J, Mori T, Smith-Powell L, Synold TW, Chen S, Wen W. Baicalin increases VEGF expression and angiogenesis by activating the ERR-α/PGC-1-α pathway. Cardiovasc Res. 2011;89(2):426-435. Source ↗
  9. Guo L, Yue M, Ma C, Wang Y, Hou J, Li H. Baicalin reduces inflammation to inhibit lung cancer via targeting SOCS1/NF-κB/STAT3 axis. Heliyon. 2024;10(8):e29361. Source ↗
  10. Wu MH, Wu K, Zhu YB, Li DC, Yang H, Zeng H. Baicalin Antagonizes Prostate Cancer Stemness via Inhibiting Notch1/NF-κB Signaling Pathway. Chin J Integr Med. 2023;29(10):914-923. Source ↗
  11. Li Y, Wang D, Liu J, Li Y, Chen D, Zhou L, Lang T, Zhou Q. Baicalin Attenuates YAP Activity to Suppress Ovarian Cancer Stemness. Onco Targets Ther. 2020;13:7151-7163. Source ↗
  12. Chen W, Wei W, Yu L, Zhang X, Huang F, Zheng Q, Wang L, Cai C. Baicalin Promotes Mammary Gland Development via Steroid-Like Activities. Front Cell Dev Biol. 2021;9:682469. Source ↗
  13. Bai DH, Gao D, Xiong Y, Chang YL, Gan X, Yang L, Wang PP, Zhang RH. Baicalin suppresses colorectal cancer proliferation and induces M1 polarization of tumor-associated macrophages by promoting proteasomal degradation of HK2. Front Immunol. 2026;17:1812964. Source ↗
  14. Dong X, Liu X, Lin D, Zhang L, Wu Y, Chang Y, Jin M, Huang G. Baicalin induces cell death of non-small cell lung cancer cells via MCOLN3-mediated lysosomal dysfunction and autophagy blockage. Phytomedicine. 2024;133:155872. Source ↗
  15. Wang C, Yang Y, Sun L, Wang J, Jiang Z, Li Y, Liu D, Sun H, Pan Z. Baicalin reverses radioresistance in nasopharyngeal carcinoma by downregulating autophagy. Cancer Cell Int. 2020;20:35. Source ↗
  16. Lin C, Tsai SC, Tseng MT, Peng SF, Kuo SC, Lin MW, Hsu YM, Lee MR, Amagaya S, Huang WW, Wu TS, Yang JS. AKT serine/threonine protein kinase modulates baicalin-triggered autophagy in human bladder cancer T24 cells. Int J Oncol. 2013;42(3):993-1000. Source ↗
  17. Zhang X, Tang X, Liu H, Li L, Hou Q, Gao J. Autophagy induced by baicalin involves downregulation of CD147 in SMMC-7721 cells in vitro. Oncol Rep. 2012;27(4):1128-1134. Source ↗
  18. Wang Q, Xu H, Zhao X. Baicalin Inhibits Human Cervical Cancer Cells by Suppressing Protein Kinase C/Signal Transducer and Activator of Transcription (PKC/STAT3) Signaling Pathway. Med Sci Monit. 2018;24:1955-1961. Source ↗
  19. Zhu M, Ying J, Lin C, Wang Y, Huang K, Zhou Y, Teng H. Baicalin Induces Apoptotic Death of Human Chondrosarcoma Cells through Mitochondrial Dysfunction and Downregulation of the PI3K/Akt/mTOR Pathway. Planta Med. 2019;85(5):360-369. Source ↗
  20. Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, Chen Y. Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res. 2012;31(1):48. Source ↗
  21. Pang H, Wu T, Peng Z, Tan Q, Peng X, Zhan Z, Song L, Wei B. Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways. J Bone Oncol. 2022;33:100415. Source ↗
  22. Jia Y, Chen L, Guo S, Li Y. Baicalin induced colon cancer cells apoptosis through miR-217/DKK1-mediated inhibition of Wnt signaling pathway. Mol Biol Rep. 2019;46(2):1693-1700. Source ↗
  23. Sun J, Yang X, Sun H, Huang S, An H, Xu W, Chen W, Zhao W, He C, Zhong X, Li T, Liu Y, Wen B, Du Q, He S. Baicalin inhibits hepatocellular carcinoma cell growth and metastasis by suppressing ROCK1 signaling. Phytother Res. 2023;37(9):4117-4132. Source ↗
  24. Yu Y, Pei M, Li L. Baicalin induces apoptosis in hepatic cancer cells in vitro and suppresses tumor growth in vivo. Int J Clin Exp Med. 2015;8(6):8958-8967. Source ↗
  25. Dou J, Wang Z, Ma L, Peng B, Mao K, Li C, Su M, Zhou C, Peng G. Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence. Oncotarget. 2018;9(28):20089-20102. Source ↗
  26. Wang Z, Ma L, Su M, Zhou Y, Mao K, Li C, Peng G, Zhou C, Shen B, Dou J. Baicalin induces cellular senescence in human colon cancer cells via upregulation of DEPP and the activation of Ras/Raf/MEK/ERK signaling. Cell Death Dis. 2018;9(2):217. Source ↗
  27. Chan FL, Choi HL, Chen ZY, Chan PS, Huang Y. Induction of apoptosis in prostate cancer cell lines by a flavonoid, baicalin. Cancer Lett. 2000;160(2):219-228. Source ↗
  28. Hou Y, Pi C, Feng X, Wang Y, Fu S, Zhang X, Zhao L, Wei Y. Antitumor Activity In Vivo and Vitro of New Chiral Derivatives of Baicalin and Induced Apoptosis via the PI3K/Akt Signaling Pathway. Mol Ther Oncolytics. 2020;19:67-78. Source ↗
  29. Peng Y, Fu ZZ, Guo CS, Zhang YX, Di Y, Jiang B, Li QW. Effects and Mechanism of Baicalin on Apoptosis of Cervical Cancer HeLa Cells In-vitro. Iran J Pharm Res. 2015;14(1):251-261. Source ↗
  30. Zakki SA, Cui ZG, Sun L, Feng QW, Li ML, Inadera H. Baicalin Augments Hyperthermia-Induced Apoptosis in U937 Cells and Modulates the MAPK Pathway via ROS Generation. Cell Physiol Biochem. 2018;45(6):2444-2460. Source ↗
  31. Zhang L, Wang X, Wang R, Zheng X, Li N, Li H, Cao X, Zhou B, Lin Y, Yang L. Baicalin potentiates TRAIL-induced apoptosis through p38 MAPK activation and intracellular reactive oxygen species production. Mol Med Rep. 2017;16(6):8549-8555. Source ↗
  32. Wen RJ, Dong X, Zhuang HW, Pang FX, Ding SC, Li N, Mai YX, Zhou ST, Wang JY, Zhang JF. Baicalin induces ferroptosis in osteosarcomas through a novel Nrf2/xCT/GPX4 regulatory axis. Phytomedicine. 2023;116:154881. Source ↗
  33. Jin Y, Wen J, Geng Z, Wang L, Fang W, Zhao H, Yan X, Chen B, Hua H, Chen W, Lin J. Baicalin Inhibits Lung Cancer Cell Proliferation and Migration via ALOX12-Mediated Ferroptosis. Anticancer Agents Med Chem. 2025;25(20):1642-1659. Source ↗
  34. Shao L, Zhu L, Su R, Yang C, Gao X, Xu Y, Wang H, Guo C, Li H. Baicalin enhances the chemotherapy sensitivity of oxaliplatin-resistant gastric cancer cells by activating p53-mediated ferroptosis. Sci Rep. 2024;14(1):10745. Source ↗
  35. Zhou JQ, Li HJ, Zeng YH, Chen HH, Liang WY, Zhang J, Ding FP. Baicalin induces ferroptosis in HepG2 cells by inhibiting ROS-mediated PI3K/Akt/FoxO3a signaling pathway. Zhongguo Zhong Yao Za Zhi. 2024;49(5):1327-1334. Source ↗
  36. Yin Z, Chen E, Cai X, Gong E, Li Y, Xu C, Ye Z, Cao Z, Pan J. Baicalin attenuates XRCC1-mediated DNA repair to enhance the sensitivity of lung cancer cells to cisplatin. J Recept Signal Transduct Res. 2022;42(3):215-224. Source ↗
  37. Abo El-Ela SR, Zaghloul RA, Eissa LA. Promising cardioprotective effect of baicalin in doxorubicin-induced cardiotoxicity through targeting toll-like receptor 4/nuclear factor-κB and Wnt/β-catenin pathways. Nutrition. 2022;102:111732. Source ↗
  38. Farouk H, Nasr M, Elbaset MA, Shabana ME, Ahmed-Farid OAH, Ahmed RF. Baicalin nanoemulsion mitigates cisplatin-induced hepatotoxicity by alleviating oxidative stress, inflammation, and restoring cellular integrity. Toxicol Appl Pharmacol. 2025;495:117231. Source ↗
  39. Zhang J, Zhang H, Deng X, Zhang N, Liu B, Xin S, Li G, Xu K. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice. Life Sci. 2018;192:46-54. Source ↗
  40. Wang H, Chang Y, Liu X, Liu L, Hua M, Li A. Protective effects of baicalin on diethyl nitrosamine-induced liver cirrhosis by suppressing oxidative stress and inflammation. Chem Biol Drug Des. 2024;103(1):e14386. Source ↗
  41. Sawicka E, Długosz A, Rembacz KP, Guzik A. The effects of coenzyme Q10 and baicalin in cisplatin-induced lipid peroxidation and nitrosative stress. Acta Pol Pharm. 2013;70(6):977-985. Source ↗
  42. Jia Y, Gengji J, Gong T, Zhang Z, Deng L. An Amorphous Solid Dispersion of Baicalin and its Oral Therapeutic Effect on Ulcerative Colitis. Pharm Res. 2024;41(12):2377-2389. Source ↗
  43. Gong WY, Zhao ZX, Liu BJ, Lu LW, Dong JC. Exploring the chemopreventive properties and perspectives of baicalin and its aglycone baicalein in solid tumors. Eur J Med Chem. 2016;126:844-852. Source ↗
  44. Capó X, Kumar R, Mishra AP, Nigam M, Waranuch N, Martorell M, Sharopov F, Calina D, Popa D, Setzer WN, Sharifi-Rad J, Pezzani R. Baicalein and baicalin in cancer therapy: Multifaceted mechanisms, preclinical evidence, and translational challenges. Semin Oncol. 2025;52(5):152377. Source ↗
  45. Li P, Tian Y, Wang H, Ji Y, Zeng H, Zhang S, Gao X, Chen X. Effect of Hepatic Impairment on the Pharmacokinetics of Baicalin in Rats: Critical Roles of Gut Microbiota and Hepatic Transporters. Pharmaceutics. 2025;17(7):851. Source ↗
  46. Liu ZM, Ma YM, Wang TM, Guo X. In vitro metabolic interconversion between baicalin and baicalein in the liver, kidney, intestine and bladder of rat. Yao Xue Xue Bao. 2008;43(6):664-668. Source ↗
  47. Akao T, Hanada M, Sakashita Y, Sato K, Morita M, Imanaka T. Efflux of baicalin, a flavone glucuronide of Scutellariae Radix, on Caco-2 cells through multidrug resistance-associated protein 2. J Pharm Pharmacol. 2007;59(1):87-93. Source ↗
  48. Wu H, Long X, Yuan F, Chen L, Pan S, Liu Y, Stowell Y, Li X. Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin. Acta Pharm Sin B. 2014;4(3):217-226. Source ↗
  49. Wu J, Chen D, Zhang R. Study on the bioavailability of baicalin-phospholipid complex by using HPLC. Biomed Chromatogr. 1999;13(7):493-495. Source ↗
  50. Heikal LA, El-Habashy SE, El-Kamel AH, Mehanna RA, Ashour AA. Bioactive baicalin rhamno-nanocapsules as phytotherapeutic platform for treatment of acute myeloid leukemia. Int J Pharm. 2024;661:124458. Source ↗
  51. Chen F, Wen Q, Jiang J, Li HL, Tan YF, Li YH, Zeng NK. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? J Ethnopharmacol. 2016;179:253-264. Source ↗
  52. Wang T, Jiang H, Cao S, Chen Q, Cui M, Wang Z, Li D, Zhou J, Wang T, Qiu F, Kang N. Baicalin and its metabolites suppresses gluconeogenesis through activation of AMPK or AKT in insulin resistant HepG-2 cells. Eur J Med Chem. 2017;141:92-100. Source ↗
  53. Li M, Shi A, Pang H, Xue W, Li Y, Cao G, Yan B, Dong F, Li K, Xiao W, He G, Du G, Hu X. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. J Ethnopharmacol. 2014;156:210-215. Source ↗
  54. Zhang Y, Zhang M, Hu G, Zhang Z, Song R. Elevated system exposures of baicalin after combinatory oral administration of rhein and baicalin: Mainly related to breast cancer resistance protein (ABCG2), not UDP-glucuronosyltransferases. J Ethnopharmacol. 2020;250:112528. Source ↗
  55. Liu R, Li X, Wei J, Liu S, Chang Y, Zhang J, Zhang J, Zhang X, Fuhr U, Taubert M, Tian X. A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers. Front Pharmacol. 2019;10:518. Source ↗
  56. National Institute of Diabetes and Digestive and Kidney Diseases. Skullcap. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): NIDDK; updated 2020. Source ↗
  57. Lee W, Ku SK, Bae JS. Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin. Arch Pharm Res. 2015;38(5):893-903. Source ↗
  58. Fan L, Zhang W, Guo D, Tan ZR, Xu P, Li Q, Liu YZ, Zhang L, He TY, Hu DL, Wang D, Zhou HH. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther. 2008;83(3):471-476. Source ↗
  59. Yu CP, Hsieh YC, Shia CS, Hsu PW, Chen JY, Hou YC, Hsieh YW. Increased Systemic Exposure of Methotrexate by a Polyphenol-Rich Herb via Modulation on Efflux Transporters Multidrug Resistance-Associated Protein 2 and Breast Cancer Resistance Protein. J Pharm Sci. 2016;105(1):343-349. Source ↗
  60. Fujita D, Saito Y, Nakanishi T, Tamai I. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride. Drug Metab Dispos. 2016;44(1):1-7. Source ↗
  61. Wei J, Liu R, Zhang J, Liu S, Yan D, Wen X, Tian X. Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption. Front Pharmacol. 2021;12:761763. Source ↗
  62. Zhu Y, Fang J, Wang H, Fei M, Tang T, Liu K, Niu W, Zhou Y. Baicalin suppresses proliferation, migration, and invasion in human glioblastoma cells via Ca(2+)-dependent pathway. Drug Des Devel Ther. 2018;12:3247-3261. Source ↗
  63. Yao X, Lin H, Guo H, Liu Y, Xu H, Liu W. Baicalin triggers ferroptosis to suppress colorectal cancer via SLC25A28-UQCRC2-regulated electron transport chain disruption. Free Radic Biol Med. 2025;245:56-70. Source ↗
  64. Pang H, Xue W, Shi A, Li M, Li Y, Cao G, Yan B, Dong F, Xiao W, He G, Du G, Hu X, Cheng G. Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers. Clin Drug Investig. 2016;36(9):713-724. Source ↗
  65. Du G, Han G, Zhang S, Lin H, Wu X, Wang M, Ji L, Lu L, Yu L, Liang W. Baicalin suppresses lung carcinoma and lung metastasis by SOD mimic and HIF-1alpha inhibition. Eur J Pharmacol. 2009;630(1-3):121-130. Source ↗
  66. Che QM, Huang XL, Li YM, Kun Z, Teruaki A, Masao H. [Studies on metabolites of baicalin in human urine]. Zhongguo Zhong Yao Za Zhi. 2001;26(11):768-769. Source ↗
  67. Zheng YC, Shen DD, Ren M, Liu XQ, Wang ZR, Liu Y, Zhang QN, Zhao LJ, Zhao LJ, Ma JL, Yu B, Liu HM. Baicalin, a natural LSD1 inhibitor. Bioorg Chem. 2016;69:129-131. Source ↗
  68. Yuan J, Khan SU, Yan J, Lu J, Yang C, Tong Q. Baicalin enhances the efficacy of 5-Fluorouracil in gastric cancer by promoting ROS-mediated ferroptosis. Biomed Pharmacother. 2023;164:114986. Source ↗

Related Reading

One Sugar Apart: Why Baicalein and Baicalin Are Not Interchangeable

In our Explainer article, we discuss how baicalin and its aglycone, baicalein, interconvert in the body — and what genuinely stays different between the two once ingested.

Last reviewed: 2026-08-10